In this latest update, we explore some of the key updates in market access over recent months including the UK's voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, and, finally, the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945425 | PMC |
http://dx.doi.org/10.57264/cer-2024-0009 | DOI Listing |
BMC Health Serv Res
January 2025
NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal.
Background: Proton-pump-inhibitors (PPIs) are overprescribed, posing challenges to patients and healthcare systems. In Portugal, the public National Health Service (NHS) provides universal coverage and reimburses medication regardless of prescription origin, i.e.
View Article and Find Full Text PDFEur J Pediatr
January 2025
Merck & Co., Inc., V&I Outcomes Research, Rahway, NJ, USA.
Nat Food
January 2025
Oxford Programme for Sustainable Infrastructure Systems, Environmental Change Institute, University of Oxford, Oxford, UK.
Despite the growing accessibility of international grain and oilseed markets, high production costs and trade frictions are still prevalent, contributing to regional heterogeneities in the landed cost of grain imports. Here we quantify the landed cost for six grain commodities across 3,500 administrative regions, capturing regional cost differences to produce grain and transport it across international borders. We find large heterogeneities in the costs of imported grain, which are highest in Oceania, Central America and landlocked Africa.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Working Group for Data-Driven Innovation, Hamburg University of Technology, Hamburg, Germany.
Background: Health care innovation faces significant challenges, including system inertia and diverse stakeholders, making regulated market access pathways essential for facilitating the adoption of new technologies. The German Digital Healthcare Act, introduced in 2019, offers a model by enabling digital health applications (DiGAs) to be reimbursed by statutory health insurance, improving market access and patient empowerment. However, the factors influencing the success of these pathways in driving innovation remain unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!